Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy
AssigneesPamGene B.V., Oslo University Hospital
InventorsPieter Jacob Boender, Richard De Wijn, Anne Hansen Ree, Sigurd Folkvord, Kjersti Flatmark, Robby Ruijtenbeek
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and/or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.
Claims12
A method for predicting the response of a patient diagnosed with rectal cancer to chemoradiotherapy, comprising the steps of:
- (a) measuring tyrosine kinase activity of a sample, obtained from the rectal cancer tumor from said patient, thereby providing the phosphorylation levels of tyrosine kinase phosphorylation sites present in at least 25 of the peptide markers of SEQ ID NOs:
- 1-86;
- and, (b) determining from said phosphorylation levels the response of said patient to chemoradiotherapy.
A method for predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy, comprising the steps of:
- (a) measuring tyrosine kinase activity of a sample, obtained from the rectal cancer tumor from said patient, thereby providing a phosphorylation profile of said sample, said phosphorylation profile comprising the phosphorylation levels of tyrosine kinase phosphorylation sites present in at least 25 of the peptide markers of SEQ ID NOs:
- 1-86;
- and, (b) determining from said phosphorylation profile the response of said patient to chemoradiotherapy.
Dependencies are inferred from the claim text.